Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Obama Pitches Part D Rx Price Concessions In State Of The Union Address

This article was originally published in The Pink Sheet Daily

Executive Summary

President Obama’s speech includes some proposals for cost-savings in Medicare, such as having wealthier seniors pay more, moving from pay-for-service to pay-for-performance and mandatory rebates on drugs used in Medicare Part D, which drew a quick response from PhRMA.

You may also be interested in...



Part D Rebates: Talking Points Continue, But Deficit Deal Elusive

Once again the President is calling for rebates on prescription drugs sold under Medicare Part D. But without a big deficit deal involving entitlement reform, is there any way to enact them?

Mandatory Part D Drug Rebates Proposed By Deficit Panel Leaders; Stronger IPAB Also On The Table

The co-chairs of the bipartisan National Commission on Fiscal Responsibility and Reform issued a cost-savings proposal for the government, including Medicare, on Nov. 10, but it will need approval by 14 of 18 members before going to the president.

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS075270

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel